Author:
Ricciuti Biagio,Brambilla Marta,Metro Giulio,Baglivo Sara,Matocci Roberta,Pirro Matteo,Chiari Rita
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology,General Medicine
Reference45 articles.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
2. American Cancer Society. Non-small cell lung cancer survival rates by stage. https://www.cancer.org/cancer/lungcancernonsmallcell/detaileddpfguide/non-small-cell-lung-cancer-survival-rates . Accessed 01 Feb 2017.
3. Passiglia F, Bronte G, Castiglia M, Listì A, Calò V, Toia F, et al. Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls? Expert Opin Biol Ther. 2015;15(11):1553–66.
4. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.
5. Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, et al. First-SIGnaL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30(10):1122–8.
Cited by
49 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献